#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	10940	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2093	513.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1418	1418	C	579	C,A	564,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	10940	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2093	513.4	0	HET	.	.	.	C207T	.	207	207	C	441	441	C	594	C,T	451,124	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	20156	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3623	550.7	0	.	n	.	0	T695C	SNP	695	695	T	1069	1069	C	602	C,T	586,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	20156	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3623	550.7	0	.	n	.	0	A1638G	SNP	1638	1638	A	2012	2012	G	634	G,A	465,146	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	20156	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3623	550.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2345	2345	C	613	C,G	596,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	20156	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3623	550.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2419	2419	A	632	A	620	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	20156	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3623	550.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	2971	2971	C	592	C,T	572,4	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	1460	folP	855	855	100.0	folP.l15.c4.ctg.1	1821	79.7	1	SNP	p	R229S	1	.	.	685	687	AGC	1161	1163	AGC	134;134;134	A;G;C	129;131;130	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3848	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3318	114.7	1	SNP	p	S91F	1	.	.	271	273	TTC	547	549	TTC	114;113;113	T;T;C	114;113;112	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3848	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3318	114.7	1	SNP	p	G95N	0	.	.	283	285	GGC	559	561	GGC	117;115;115	G;G;C	114;112;111	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3848	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3318	114.7	1	SNP	p	D95G	1	.	.	283	285	GGC	559	561	GGC	117;115;115	G;G;C	114;112;111	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1254	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1568	79.1	1	SNP	p	G45D	0	.	.	133	135	GGC	610	612	GGC	159;159;160	G;G,A;C	159;157,1;159	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	718	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1149	62.0	0	.	n	.	0	A197.	DEL	197	197	A	642	642	A	170	A	164	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3578	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3131	113.3	1	SNP	p	D86N	0	.	.	256	258	GAC	689	691	GAC	147;145;145	G;A;C	141;137;141	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3578	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3131	113.3	1	SNP	p	R87W	0	.	.	259	261	CGT	692	694	CGT	146;149;151	C,A;G,A;T	140,2;144,1;141	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3578	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3131	113.3	1	SNP	p	S87R	1	.	.	259	261	CGT	692	694	CGT	146;149;151	C,A;G,A;T	140,2;144,1;141	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3578	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3131	113.3	1	SNP	p	R87I	0	.	.	259	261	CGT	692	694	CGT	146;149;151	C,A;G,A;T	140,2;144,1;141	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3578	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3131	113.3	1	SNP	p	S88P	0	.	.	262	264	TCC	695	697	TCC	153;152;152	T;C;C	143;144;147	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3184	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2793	113.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1650	1652	GGC	150;145;145	G;G;C	147;140;139	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	3038	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2341	128.1	1	SNP	p	A311V	0	.	.	931	933	GCC	1281	1283	GCC	173;174;176	G;C;C	165;169;170	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3038	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2341	128.1	1	SNP	p	I312M	1	.	.	934	936	ATG	1284	1286	ATG	177;175;174	A,C;T;G	173,1;170;167	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3038	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2341	128.1	1	SNP	p	T316P	0	.	.	946	948	ACC	1296	1298	ACC	172;171;170	A,G;C;C	161,1;164;163	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3038	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2341	128.1	1	SNP	p	V316T	1	.	.	946	948	ACC	1296	1298	ACC	172;171;170	A,G;C;C	161,1;164;163	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3038	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2341	128.1	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1797	1799	ACC	131;131;130	A,G;C;C,T	126,1;128;127,1	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3038	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2341	128.1	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1851	1853	GCG	133;133;135	G;C;G	130;129;132	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3038	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2341	128.1	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1851	1853	GCG	133;133;135	G;C;G	130;129;132	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3038	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2341	128.1	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1974	1976	GGT	104;103;103	G;G;T,C	101;102;98,1	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3038	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2341	128.1	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1983	1985	AGC	93;92;92	A,G;G;C	90,1;90;91	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3038	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2341	128.1	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2001	2003	CCG	64;65;63	C,G;C;G	59,1;60;57	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4094	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3262	124.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1742	1744	CCG	142;140;142	C;C,T;G	134;133,2;136	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1938	porA	1146	1146	99.91	porA.l15.c17.ctg.1	1937	98.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	510	510	C	128	C,G	123,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	516	190	porB1a	984	270	90.74	porB1a.l6.c17.ctg.3	418	9.1	0	.	p	.	0	A251V	NONSYN	751	753	GCG	37	39	GTA	11;11;11	G;T;A	7;7;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	516	190	porB1a	984	270	90.74	porB1a.l6.c17.ctg.3	418	9.1	0	.	p	.	0	S271T	NONSYN	811	813	TCG	97	99	ACT	19;17;17	A,T;C;T,G	16,2;15;15,2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	516	190	porB1a	984	270	90.74	porB1a.l6.c17.ctg.3	418	9.1	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	103	105	GAT	17;17;16	G,T;A;T	14,2;16;16	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	516	190	porB1a	984	270	90.74	porB1a.l6.c17.ctg.3	418	9.1	0	.	p	.	0	D276N	NONSYN	826	828	GAT	112	114	AAC	17;17;17	A,G;A;C,T	15,2;17;14,2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	516	190	porB1a	984	270	90.74	porB1a.l6.c17.ctg.3	418	9.1	0	.	p	.	0	N277H	NONSYN	829	831	AAC	115	117	CAC	17;17;17	C,A;A;C	15,2;17;17	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	516	190	porB1a	984	270	90.74	porB1a.l6.c17.ctg.3	418	9.1	0	.	p	.	0	R307E	NONSYN	919	921	AGA	205	207	GAA	4;4;4	G;A;A	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	516	190	porB1a	984	270	90.74	porB1a.l6.c17.ctg.3	418	9.1	0	.	p	.	0	T311A	NONSYN	931	933	ACA	217	219	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	516	190	porB1a	984	270	90.74	porB1a.l6.c17.ctg.3	418	9.1	0	.	p	.	0	E312D	NONSYN	934	936	GAA	220	222	GAC	3;3;3	G;A;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	516	190	porB1a	984	270	90.74	porB1a.l6.c17.ctg.3	418	9.1	0	.	p	.	0	F314I	NONSYN	940	942	TTC	226	228	ATC	3;2;2	A;T;C	3;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	516	190	porB1a	984	270	90.74	porB1a.l6.c17.ctg.3	418	9.1	0	.	p	.	0	A316S	NONSYN	946	948	GCG	232	234	TCG	2;2;2	T;C;G	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	516	190	porB1a	984	270	90.74	porB1a.l6.c17.ctg.3	418	9.1	0	.	p	.	0	V318A	NONSYN	952	954	GTC	238	240	GCC	3;3;3	G;C;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	516	190	porB1a	984	270	90.74	porB1a.l6.c17.ctg.3	418	9.1	0	.	p	.	0	G319S	NONSYN	955	957	GGC	241	243	AGC	3;3;3	A;G;C	2;3;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	516	190	porB1a	984	270	90.74	porB1a.l6.c17.ctg.3	418	9.1	0	.	p	.	0	G320A	NONSYN	958	960	GGT	244	246	GCC	2;2;2	G;C;C	2;2;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	516	190	porB1a	984	270	90.74	porB1a.l6.c17.ctg.3	418	9.1	0	.	p	.	0	G322V	NONSYN	964	966	GGT	250	252	GTT	2;2;2	G;T;T	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	516	190	porB1a	984	270	90.74	porB1a.l6.c17.ctg.3	418	9.1	0	.	p	.	0	H325Q	NONSYN	973	975	CAC	259	261	CAA	1;1;1	C;A;A	0;1;0	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	516	190	porB1a	984	270	90.74	porB1a.l6.c17.ctg.3	418	9.1	0	.	p	.	0	K326N	NONSYN	976	978	AAA	262	264	AAT	1;1;1	A;A;T	1;1;0	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	516	190	porB1a	984	386	97.53	porB1a.l6.c17.ctg.4	380	1.8	0	.	p	.	0	A29V	NONSYN	85	87	GCC	67	69	GTC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	516	190	porB1a	984	386	97.53	porB1a.l6.c17.ctg.4	380	1.8	0	.	p	.	0	Y201F	NONSYN	601	603	TAC	169	171	TTC	4;4;4	T;T,A;C	4;3,1;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	516	190	porB1a	984	386	97.53	porB1a.l6.c17.ctg.4	380	1.8	0	.	p	.	0	S236R	NONSYN	706	708	AGC	274	276	CGC	2;2;2	C,A;G;C	1,1;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	516	190	porB1a	984	386	97.53	porB1a.l6.c17.ctg.4	380	1.8	0	.	p	.	0	A251V	NONSYN	751	753	GCG	319	321	GTA	3;3;3	G;T,C;A,G	3;0,3;0,3	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2150	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1780	118.9	1	SNP	p	G120K	1	.	.	358	360	AAG	754	756	AAG	179;182;179	A,G;A,G;G,C	166,2;178,2;167,1	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2150	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1780	118.9	1	SNP	p	N121D	0	.	.	361	363	AAC	757	759	AAC	181;181;181	A,G;A,C;C,A	174,4;175,2;173,1	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2150	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1780	118.9	1	SNP	p	A121N	1	.	.	361	363	AAC	757	759	AAC	181;181;181	A,G;A,C;C,A	174,4;175,2;173,1	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	7340	rpoB	4179	4179	99.98	rpoB.l15.c17.ctg.1	4859	149.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	880	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1138	76.4	1	SNP	p	V57M	1	.	.	169	171	ATG	505	507	ATG	165;164;164	A;T;G	161;157;157	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
